World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
62900
World Ranking
10237
National Ranking
5264

Sandra M. Swain publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sandra M. Swain sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 475 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sandra M. Swain D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sandra M. Swain sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sandra M. Swain is affiliated with Georgetown University Medical Center in the United States and has made significant contributions in the field of medical research, particularly in oncology. Their research focuses extensively on breast cancer, with a strong emphasis on HER2-positive breast cancer and advanced breast cancer therapies.

Their work spans a broad range of topics within medicine and biochemistry, genetics, and molecular biology, with a concentration on oncology and cancer research. Subfields of study include pulmonary and respiratory medicine, genetics, and radiology, nuclear medicine, and imaging. Key thematic areas addressed in their publications include:

  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Their research is frequently published in prominent venues such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Breast Cancer Research and Treatment
  • Cancers
  • Annals of Oncology

Notable recent papers authored by Sandra M. Swain include:

  • Targeting HER2-positive breast cancer: advances and future directions, 2022, Nature Reviews Drug Discovery
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management, 2022, Cancer Treatment Reviews

Frequent collaborators in their research include:

  • Charles E. Geyer
  • Priya Rastogi
  • Norman Wolmark
  • Eleftherios P. Mamounas
  • Paula R. Pohlmann

Best Publications

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

    Sandra M. Swain;Fredrick S. Whaley;Michael S. Ewer

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

    R Peto;C Davies;J Godwin

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

    José Baselga;Sandra M. Swain

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31

    Elizabeth Tan-Chiu;Greg Yothers;Edward Romond;Charles E. Geyer

  • Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Edith A. Perez;Edward H. Romond;Vera J. Suman;Jong Hyeon Jeong

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

    Irene L. Wapnir;James J. Dignam;Bernard Fisher;Eleftherios P. Mamounas

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

    Sandra M. Swain;Fredrick S. Whaley;Miriam C. Gerber;Steven Weisberg

  • Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

    Kip A. West;John Brognard;Amy S. Clark;Ilona R. Linnoila

  • Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

    Carolyn Taylor;Candace Correa;Frances K Duane;Marianne C Aznar

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Bevacizumab added to neoadjuvant chemotherapy for breast cancer

    Harry D. Bear;Gong Tang;Priya Rastogi;Charles E. Geyer

  • Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

    Suparna Bonthala Wedam;Jennifer A. Low;Sherry X. Yang;Catherine K. Chow

Frequent Co-Authors

Eleftherios P. Mamounas
Eleftherios P. Mamounas University of Florida Health
Norman Wolmark
Norman Wolmark University of Pittsburgh
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Joseph P. Costantino
Joseph P. Costantino University of Pittsburgh
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Soonmyung Paik
Soonmyung Paik Yonsei University
Adam Brufsky
Adam Brufsky University of Pittsburgh
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always require following the traditional path of attending medical school. For many students, flexible online degree programs can open doors to rewarding healthcare roles without disrupting personal or professional commitments.

Aspiring nurse practitioners can explore the cheapest online BSN to DNP programs. These advanced nursing degrees are designed for registered nurses seeking leadership or clinical expert roles, and online study can significantly reduce time and costs.

Those interested in pharmacy can consider obtaining an online pharmacist degree. These programs prepare students for diverse pharmacy careers, combining rigorous coursework with flexible remote learning.

Not all healthcare careers focus on direct patient care. Earning an online bachelor's in health information management can lead to roles in healthcare administration, data management, and compliance.

For those looking for quicker entry into the healthcare field, exploring medical coding certification cost and online programs can help you qualify for high-demand roles in medical billing and coding, supporting the healthcare system’s essential behind-the-scenes functions.

Best Scientists Citing Sandra M. Swain

Trending Scientists

Recently Published Articles